# Structural and Computational Analysis of Pseudomonas aeruginosa DNA Gyrase Reveals Molecular Characteristics That May Contribute to Ciprofloxacin Resistance

**Authors:** Lalith Perera, Libertad García-Villada, Andrea M. Kaminski, Natalya Degtyareva, Lars C. Pedersen, Paul W. Doetsch

PMC · DOI: 10.3390/biom16020318 · Biomolecules · 2026-02-18

## TL;DR

This study explores how mutations in Pseudomonas aeruginosa DNA gyrase lead to resistance against the antibiotic ciprofloxacin.

## Contribution

The paper provides structural and computational insights into the molecular mechanisms of ciprofloxacin resistance in P. aeruginosa.

## Key findings

- DNA stabilizes ciprofloxacin binding more than specific GyrA residues.
- A solvent cavity near GyrA residues may influence ciprofloxacin access to the active site.
- Mutations increase repulsive potential, potentially hindering ciprofloxacin binding.

## Abstract

Pseudomonas aeruginosa is considered a priority pathogen by the World Health Organization due to its resistance to antibiotics. Isolates resistant to ciprofloxacin (CPFX), a bactericide commonly used against P. aeruginosa, usually carry the mutations T83I or D87N in the GyrA subunit of the DNA gyrase. Yet, the molecular mechanisms by which these mutations confer CPFX-resistance to P. aeruginosa are unknown. Here we solved the crystal structure of the P. aeruginosa gyrase catalytic cleavage core and used it to carry out molecular dynamic (MD) simulations of CPFX-gyrase binding in the wild-type as well as the T83I and the D87N mutant systems. Our results show that DNA plays the most prominent stabilizing role once CPFX is bound, with relatively minor contributions from Thr83 or Asp87. Interestingly, we found a solvent cavity adjacent to these residues that may provide CPFX access to the active site. Interaction energy analysis using Umbrella Sampling indicates that Thr83 and Asp87 may influence CPFX trajectory during binding. In the mutant systems, the repulsive potential increases at the cavity site, which may hinder CPFX accessing the binding site. These results shed light on P. aeruginosa resistance to CPFX and may help provide a methodology to identify new therapeutic agents to target fluoroquinolone resistant bacteria.

## Linked entities

- **Proteins:** GYRA (DNA GYRASE A)
- **Chemicals:** ciprofloxacin (PubChem CID 2764), CPFX (PubChem CID 2764)
- **Species:** Pseudomonas aeruginosa (taxon 287)

## Full-text entities

- **Diseases:** injury to (MESH:D014947), cystic fibrosis (MESH:D003550), chronic lung infections (MESH:D055370), chronic obstructive pulmonary disease (MESH:D029424), nosocomial infections (MESH:D003428), P. aeruginosa infections (MESH:D011552), Infections (MESH:D007239)
- **Chemicals:** MgCl2 (MESH:D015636), NaCl (MESH:D012965), phosphate (MESH:D010710), salt (MESH:D012492), acid (MESH:D000143), -oxygen (MESH:D010100), ethylene glycol (MESH:D019855), ethidium bromide (MESH:D004996), nitrogen (MESH:D009584), bromophenol blue (MESH:D001978), EDTA (MESH:D004492), CPFX (MESH:D002939), delafloxacin (MESH:C477891), carbon (MESH:D002244), tyrosine (MESH:D014443), H2O (MESH:D014867), nucleotide (MESH:D009711), peptide (MESH:D010455), DTT (MESH:D004229), PEG 4000 (MESH:C000595214), MnCl2 (MESH:C025340), sarkosyl (MESH:C025231), 3NUH (-), HEPES (MESH:D006531), glycerol (MESH:D005990), Na+ (MESH:D012964), Amino acid (MESH:D000596), Cl- (MESH:D002713), Quinolone (MESH:D015363), fluoroquinolone (MESH:D024841), Brij35 (MESH:C515901), ATP (MESH:D000255), quinoline (MESH:C037219), ampicillin (MESH:D000667), IPTG (MESH:D007544), citrate (MESH:D019343), piperazine (MESH:D000077489), agarose (MESH:D012685), ammonium sulfate (MESH:D000645), sodium acetate (MESH:D019346), Mg (MESH:D008274), chloramphenicol (MESH:D002701), manganese (MESH:D008345), PEG 8000 (MESH:C000595216)
- **Species:** Mycobacterium tuberculosis subsp. tuberculosis (subspecies) [taxon 182785], Escherichia coli (E. coli, species) [taxon 562], Pseudomonas aeruginosa (species) [taxon 287], Klebsiella pneumoniae (species) [taxon 573], Enterobacter (genus) [taxon 547], Streptococcus pneumoniae (species) [taxon 1313], Colwellia psychrerythraea (species) [taxon 28229], aureus [taxon 46170], Staphylococcus aureus (species) [taxon 1280], Mycobacterium tuberculosis (species) [taxon 1773], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Homo sapiens (human, species) [taxon 9606], Acinetobacter baumannii (species) [taxon 470], Enterococcus faecium (species) [taxon 1352], Tobacco etch virus (no rank) [taxon 12227]
- **Mutations:** Asp87, Asp87, S85P, Glu88, T83I, Ile83, S84L, Asp87 with Asn, E88K, Thr83, Y123F, Thr83, Ser84, Histidine residues 132, D87N, Ser85, T83, Asn87, T83I

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938007/full.md

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938007/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938007/full.md

---
Source: https://tomesphere.com/paper/PMC12938007